A Phase 3 interventional study of Laboratory Biomarker Analysis and Lapatinib Ditosylate in Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7 and Stage IIB Breast Cancer AJCC v6 and v7, sponsored by National Cancer Institute (NCI). Completed at 318 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by National Cancer Institute (NCI) · Phase 3, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing trastuzumab in Breast Neoplasms, Male — none open to participants now, 1 under way, none of them phase 3. Trastuzumab · Breast Neoplasms, Male.
Among the 14 studies testing trastuzumab in Breast Neoplasms, Male, this one has the largest enrollment, is one of 3 that started in 2009, is the only one in phase 3, and was the 12th registered.
286 studies on the registry are indexed under Breast Neoplasms, Male; 5 are open to participants now.
Browse Breast Neoplasms, Male studies →None of the 14 studies testing trastuzumab in Breast Neoplasms, Male is open now. The open studies under Breast Neoplasms, Male, anywhere →
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 5 Breast Neoplasms, Male studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 1
First in 1999; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 305 is above the median of 37 across 230 interventional studies indexed under Breast Neoplasms, Male.
Median enrollment 51 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 9 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
57 studies in Breast Neoplasms, Male by National Cancer Institute (NCI): none open now, none under way, none of them phase 3. Of 57 finished, 18 (32%) have results posted.
Among the 57 studies in Breast Neoplasms, Male by National Cancer Institute (NCI), this one is the 2nd largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2009, is the only one in phase 3, and was the 42nd registered.
National Cancer Institute (NCI)’s Breast Neoplasms, Male studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing trastuzumab in Breast Neoplasms, Male, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among National Cancer Institute (NCI)’s 57 in Breast Neoplasms, Male:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel with trastuzumab and/or lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which regimen is more effective in treating patients with breast cancer.
PRIMARY OBJECTIVE:
I. To determine if the pathologic complete response (pCR) in the breast to neoadjuvant weekly paclitaxel with trastuzumab plus lapatinib (THL) is 20% greater than the pCR to weekly paclitaxel with trastuzumab alone (TH).
SECONDARY OBJECTIVES:
I. To determine the pathologic complete response in the breast and axilla, using American Joint Committee on Cancer (AJCC) Tumor, Lymph Nodes and Metastasis (TMN) criteria (version 6), to neoadjuvant weekly paclitaxel plus human epidermal growth factor 2 (HER2)- targeted therapy in patients with HER2-positive operable breast cancer.
II. To evaluate residual cancer burden (RCB) as a predictor of long term relapse free survival (RFS) and overall survival (OS).
III. To document the toxicity of all chemotherapeutic regimens (THL, TH). IV. To determine the correlation between clinical, radiographic and pathologic response.
V. To compare overall survival (OS), relapse free survival (RFS) and time to first failure (TFF) among the treatment groups.
VI. To obtain blood, fresh frozen and fixed tumor tissue to test specific hypotheses for which biomarker data exist and to evaluate biomarkers in blood, serum and tissue that are likely to influence response to and toxicity of trastuzumab alone or trastuzumab plus lapatinib, when given with paclitaxel.
VII. To determine the surgical practice patterns for breast conservation and sentinel lymphadenectomy in patients undergoing neoadjuvant chemotherapy.
VIII. To determine the radiotherapy practice patterns for post-mastectomy and regional nodal irradiation in patients undergoing neoadjuvant chemotherapy.
IX. To evaluate pharmacogenomic determinants of toxicity.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive trastuzumab IV over 30-90 minutes and paclitaxel IV over 1 hour once weekly and lapatinib ditosylate orally (PO) once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive trastuzumab and paclitaxel as in arm I.
ARM III: Patients receive paclitaxel and lapatinib ditosylate as in arm I. (Discontinued as of 6-15-11) Within 42 days after completion of neoadjuvant therapy, patients in both arms undergo definitive surgery (breast conservation or total mastectomy).
After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 10 years.
Inclusion Criteria:
Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after therapy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m\^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis · Drug: Lapatinib Ditosylate · Drug: Paclitaxel · Biological: Trastuzumab
Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m\^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis · Drug: Paclitaxel · Biological: Trastuzumab
Patients receive paclitaxel 80 mg/m\^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)
Drug: Lapatinib Ditosylate · Drug: Paclitaxel
Correlative studies
Given PO
Also known as: Tykerb
Given IV
Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
Given IV
Also known as: ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac
pCR Rate
Complete pathological response is defined as the absence of residual invasive carcinoma in the breast at the time of definitive surgical removal. Pathologic complete response in the lymph nodes is defined as no detectable invasive tumor by H\&E. Analysis will use a chi-square test for the difference in proportions of patients on the THL arm versus the TH arm who achieve a pCR. Exact binomial methods will be used to construct 95% confidence intervals around the pCR incidence for each arm.
Time frame: At time of surgery
Pathologic Stage in the Breast and Axilla
Stage will be determined by the American Joint Committee on Cancer (AJCC) TNM (tumor, lymph nodes, metastasis) staging system. yT0: No evidence of residual invasive primary tumor. yTis: Carcinoma in situ only (presence of ductal carcinoma in situ \[DCIS\] but completely free of invasive cancer). yT1: Residual invasive tumor \<= 2 in greatest dimension.yT2: Residual invasive tumor \> 2 cm but \<= 5 cm in greatest dimension.yT3: Residual invasive tumor \> 5 cm in greatest dimension.yT4: Residual tumor of any size with direct extension to the chest wall and/or skin (including ulceration or macroscopic nodules).
Time frame: At time of surgery
Radiographic Response Rate (at Completion of Neoadjuvant Therapy)
Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). A responding participant had either a complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions).
Time frame: Week 16
Overall Survival Rate
Overall survival was measured as the interval from study entry until death, from any cause, or last contact. Distribution was estimated using the Kaplan Meier product-limit method
Time frame: Time from randomization to death or last follow-up (up to 10 years)
Relapse-free Survival (RFS) Rate
Relapse free survival is defined as the interval from definitive surgery to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, or death from any cause, whichever occurs first. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Patients who do not undergo definitive surgery will not be assessable for RFS. Distribution was estimated using the Kaplan Meier product-limit method. Relapse-free survival (RFS) Rate is the rate of patients alive and relapse free.
Time frame: Time from surgery to any recurrence (up to 10 years)
Time to First Failure
Time to first failure is defined as the interval from study entry to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence or death from any cause. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Distribution was estimated using the Kaplan Meier product-limit method.
Time frame: Time from surgery to any recurrence (up to 10 years)
Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3
The type and grade of treatment-related toxicity will be tabulated by treatment arm.
Time frame: Up to 30 days post-treatment
| Milestone | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| Started | 118 | 120 | 67 |
| Completed | 101 | 110 | 44 |
| Not completed | 17 | 10 | 23 |
| Withdrew: Adverse event | 9 | 1 | 12 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 7 |
| Withdrew: Progression | 2 | 2 | 0 |
| Withdrew: Complicating illness | 0 | 0 | 1 |
| Withdrew: Other medical reasons | 2 | 4 | 3 |
Complete pathological response is defined as the absence of residual invasive carcinoma in the breast at the time of definitive surgical removal. Pathologic complete response in the lymph nodes is defined as no detectable invasive tumor by H\&E. Analysis will use a chi-square test for the difference in proportions of patients on the THL arm versus the TH arm who achieve a pCR. Exact binomial methods will be used to construct 95% confidence intervals around the pCR incidence for each arm.
| percentage of participants | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| pCR Rate | 56 (47 to 65) | 46 (35 to 55) | 32 (22 to 45) |
Stage will be determined by the American Joint Committee on Cancer (AJCC) TNM (tumor, lymph nodes, metastasis) staging system. yT0: No evidence of residual invasive primary tumor. yTis: Carcinoma in situ only (presence of ductal carcinoma in situ \[DCIS\] but completely free of invasive cancer). yT1: Residual invasive tumor \<= 2 in greatest dimension.yT2: Residual invasive tumor \> 2 cm but \<= 5 cm in greatest dimension.yT3: Residual invasive tumor \> 5 cm in greatest dimension.yT4: Residual tumor of any size with direct extension to the chest wall and/or skin (including ulceration or macroscopic nodules).
| Participants | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| yT0 | 50 | 41 | 13 |
| yT1 | 37 | 44 | 31 |
| yT2 | 7 | 12 | 8 |
| yT3 | 3 | 5 | 3 |
| yT4 | 0 | 2 | 0 |
| yTi | 17 | 13 | 7 |
| Missing | 4 | 3 | 5 |
Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). A responding participant had either a complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions).
| Participants | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| CR | 38 | 48 | 20 |
| PD | 1 | 2 | 1 |
| PR | 38 | 42 | 26 |
| SD | 15 | 11 | 3 |
| Missing | 26 | 17 | 17 |
Overall survival was measured as the interval from study entry until death, from any cause, or last contact. Distribution was estimated using the Kaplan Meier product-limit method
| proportion of participants | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| Overall Survival Rate | 0.96 (0.92 to 0.99) | 0.87 (0.8 to 0.94) | 0.85 (0.76 to 0.95) |
Relapse free survival is defined as the interval from definitive surgery to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, or death from any cause, whichever occurs first. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Patients who do not undergo definitive surgery will not be assessable for RFS. Distribution was estimated using the Kaplan Meier product-limit method. Relapse-free survival (RFS) Rate is the rate of patients alive and relapse free.
| proportion of participants | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| Relapse-free Survival (RFS) Rate | 0.93 (0.88 to 0.98) | 0.77 (0.69 to 0.86) | 0.71 (0.60 to 0.84) |
Time to first failure is defined as the interval from study entry to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence or death from any cause. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Distribution was estimated using the Kaplan Meier product-limit method.
| proportion of participants | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| Time to First Failure | 0.93 (0.88 to 0.98) | 0.79 (0.71 to 0.87) | 0.69 (0.58 to 0.82) |
The type and grade of treatment-related toxicity will be tabulated by treatment arm.
| Participants | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| Neutrophils | 8 | 2 | 8 |
| Rash | 16 | 2 | 10 |
| Diarrhea | 25 | 2 | 14 |
| Febrile neutropenia | 0 | 0 | 1 |
| Increased ALT | 6 | 1 | 3 |
| Increased AST | 4 | 0 | 3 |
| Sensory neuropathy | 11 | 4 | 3 |
| Thrombosis | 1 | 0 | 0 |
| Hypokalemia | 7 | 0 | 1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I (THL) | — | 15/115 (13%) | 114/115 (99.1%) |
| Arm II (TH) | — | 12/115 (10.4%) | 114/115 (99.1%) |
| Arm III (TL) | — | 6/65 (9.2%) | 64/65 (98.5%) |
| Event | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 12/115 | 5/115 | 5/65 |
| FatigueGeneral disorders | 11/115 | 8/115 | 4/65 |
| Hemoglobin decreasedBlood and lymphatic system disorders | 9/115 | 7/115 | 4/65 |
| Rash desquamatingSkin and subcutaneous tissue disorders | 5/115 | 2/115 | 4/65 |
| NauseaGastrointestinal disorders | 7/115 | 2/115 | 2/65 |
| Peripheral sensory neuropathyNervous system disorders | 6/115 | 4/115 | 1/65 |
| Alanine aminotransferase increasedInvestigations | 1/115 | 2/115 | 3/65 |
| Neutrophil count decreasedInvestigations | 5/115 | 3/115 | 2/65 |
| Aspartate aminotransferase increasedInvestigations | 2/115 | 1/115 | 2/65 |
| VomitingGastrointestinal disorders | 3/115 | 1/115 | 1/65 |
| Event | Arm I (THL) | Arm II (TH) | Arm III (TL) |
|---|---|---|---|
| FatigueGeneral disorders | 101/115 | 97/115 | 47/65 |
| DiarrheaGastrointestinal disorders | 100/115 | 55/115 | 56/65 |
| Peripheral sensory neuropathyNervous system disorders | 92/115 | 84/115 | 44/65 |
| Rash desquamatingSkin and subcutaneous tissue disorders | 83/115 | 49/115 | 48/65 |
| Hemoglobin decreasedBlood and lymphatic system disorders | 74/115 | 72/115 | 40/65 |
| NauseaGastrointestinal disorders | 61/115 | 45/115 | 32/65 |
| Neutrophil count decreasedInvestigations | 41/115 | 29/115 | 19/65 |
| MyalgiaMusculoskeletal and connective tissue disorders | 28/115 | 34/115 | 22/65 |
| VomitingGastrointestinal disorders | 18/115 | 13/115 | 16/65 |
| Alanine aminotransferase increasedInvestigations | 15/115 | 9/115 | 6/65 |
| Age, Continuous(years) | Arm I (THL) | Arm II (TH) | Arm III (TL) | Total |
|---|---|---|---|---|
| Median | 48.5 (24.7 to 70.8) | 50.3 (30.2 to 75.8) | 48.3 (25.8 to 74.3) | 49.4 (24.7 to 75.8) |
| Sex: Female, Male(Participants) | Arm I (THL) | Arm II (TH) | Arm III (TL) | Total |
|---|---|---|---|---|
| Female | 117 | 119 | 67 | 303 |
| Male | 1 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Arm I (THL) | Arm II (TH) | Arm III (TL) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 4 | 8 | 5 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 12 | 8 | 7 | 27 |
| White | 95 | 97 | 51 | 243 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 4 | 5 | 4 | 13 |
| Region of Enrollment(participants) | Arm I (THL) | Arm II (TH) | Arm III (TL) | Total |
|---|---|---|---|---|
| United States | 118 | 120 | 67 | 305 |
| Clinical Stage(participants) | Arm I (THL) | Arm II (TH) | Arm III (TL) | Total |
|---|---|---|---|---|
| Stage II | 81 | 80 | 48 | 209 |
| Stage III | 37 | 40 | 19 | 96 |
| Hormone Receptor Status(participants) | Arm I (THL) | Arm II (TH) | Arm III (TL) | Total |
|---|---|---|---|---|
| ER/PgR Positive | 70 | 70 | 39 | 179 |
| ER/PgR or Negative | 48 | 50 | 28 | 126 |
Showing the first 100 of 318 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2009 to primary completion in Jan 2014, 59 months.
Results were first posted in May 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab
National Cancer Institute (NCI) →